Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection – A Randomized Trial

RCT (n=829) found no difference between hydroxychloroquine and control (ascorbic acid) groups in SARS-CoV-2 acquisition by day 14 (53 vs. 45 events; adjusted hazard ratio, 1.10 [95% CI, 0.73 to 1.66]; P > 0.20); excluding effect of hydroxychloroquine as postexposure prophylaxis.

Annals of Internal Medicine